News
PBM
3.145
+1.78%
0.055
DEA looks to increase legal psychedelics production for medical research
Seeking Alpha · 3d ago
Weekly Report: what happened at PBM last week (1102-1106)?
Weekly Report · 4d ago
Short Interest Alert: Most and least shorted sub-$2B healthcare stock at the end of October
Seeking Alpha · 11/03 15:15
Weekly Report: what happened at PBM last week (1026-1030)?
Weekly Report · 11/02 10:17
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/30 12:05
'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana Moment
Benzinga · 10/29 16:27
Pacific Booker Minerals Inc. Upsizes Private Placement to $12.0 Million
NASDAQ · 10/26 10:53
Weekly Report: what happened at PBM last week (1019-1023)?
Weekly Report · 10/26 10:17
Psychedelic: Optimi completes MDMA production for three programs
TipRanks · 10/22 14:05
Psyence BioMed Boosts PsyLabs Stake as U.S. Ibogaine Milestones Hit
TipRanks · 10/21 11:28
Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896
Benzinga · 10/21 11:06
Weekly Report: what happened at PBM last week (1012-1016)?
Weekly Report · 10/19 10:17
Weekly Report: what happened at PBM last week (1005-1009)?
Weekly Report · 10/12 10:22
Psyence BioMed Sets U.S. Ibogaine Manufacturing Pathway With Benuvia
NASDAQ · 10/05 11:51
Psyence Biomedical Strikes U.S. Ibogaine Manufacturing Deal with DEA-Registered Benuvia
TipRanks · 10/05 11:28
Psyence Biomedical teams with Benuvia to establish U.S. manufacture of ibogaine
TipRanks · 10/05 11:11
Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient
Benzinga · 10/05 11:06
Weekly Report: what happened at PBM last week (0928-1002)?
Weekly Report · 10/05 10:21
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Barchart · 10/05 06:00
Psychedelic: Psyence BioMed announces exclusive U.S. ibogaine license
TipRanks · 10/01 14:30
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.